Gene Therapy Rare Disease Deal Benchmarks

Gene therapy for rare diseases represents the highest-value intersection of modality and therapeutic area in biopharma licensing. Phase 1 gene therapy deals for orphan indications carry a median total deal value of $2.3B, with upfront payments of $237M. The curative one-time treatment model, combined with orphan drug exclusivity and premium pricing ($1M-$3.5M per patient), creates compelling deal economics even at early clinical stages.

Development milestones average $706M, reflecting the extensive de-risking required around vector tropism, transgene expression durability, and immunogenicity management. Regulatory milestones of $544M reward the accelerated approval pathways (surrogate endpoints, smaller trial sizes) available to orphan gene therapies. Commercial milestones reach $766M.

Royalty rates for rare disease gene therapy licensing range from 6.2% to 12.4% at the base tier. The unique economics of one-time curative treatments at $1M+ price points mean that commercial milestones are often structured around patient counts and treatment center expansion rather than traditional revenue thresholds. Zolgensma ($2.1M per treatment) and Hemgenix ($3.5M per treatment) set the pricing precedent.